(Hypertension. 2000;35:1055.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the Vascular Pathophysiology Unit, School of Medicine, University of Navarra, Pamplona, Spain.
Correspondence to Javier Díez, MD, PhD, Unidad de Fisiopatología Vascular, Facultad de Medicina, C/Irunlarrea s/n, 31080 Pamplona, Spain. E-mail jadimar{at}unav.es
| Abstract |
|---|
|
|
|---|
Key Words: endothelium rats, inbred SHR superoxides hypertrophy
| Introduction |
|---|
|
|
|---|
Several observations suggest that the nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide phosphate (NADH/NADPH) oxidase system accounts for the majority of ·O2- generation in the vessel wall.13 14 The vascular NADH/NADPH oxidase appears to be structurally and functionally different from the neutrophil oxidase. The endothelial and VSMC NADH/NADPH oxidases are probably not all similar. All components of the NADPH-oxidase enzyme have been found in endothelial cells.15 In contrast, only p22phox could be identified in VSMCs and has been shown to participate in the increased ·O2- production on stimulation with angiotensin II.16
We have hypothesized that stimulation of NADH/NADPH oxidase may contribute to increased vascular ·O2- production in SHR. Thus, the present study was designed to test whether NADH/NADPH oxidase activity is enhanced and p22phox gene expression is upregulated in the aortas of SHR. In addition, we also investigated whether blockade of angiotensin II type 1 (AT1) receptors with irbesartan modifies the enzyme in SHR.
| Methods |
|---|
|
|
|---|
Systolic blood pressure (SBP) was measured every 2 weeks by the standard tail-cuff method. For measurement of isometric wall tension and enzymatic and molecular studies, rats were killed by decapitation. The thoracic aorta then was carefully excised and dissected, adventitial tissues were carefully removed, and the vascular wall was washed thoroughly with normal saline to remove any contaminating blood.
Measurement of ·O2- Production
in Aortic Homogenates
Vascular ·O2- was
estimated with lucigenin-enhanced chemiluminescence.17
Aortic segments (2 to 3 cm) were placed in chilled modified Krebs/HEPES
buffer and homogenized on ice with a glass/glass
motor-driven tissue homogenizer for 2 minutes in
50 mmol/L PBS, which contained 0.01 mmol/L EDTA. In some
experiments the endothelium was removed by rubbing. The
homogenate was centrifuged at 1000g for
10 minutes. The pellet was discarded and the supernatant was stored on
ice until use. Protein content was measured by the method of
Bradford.18 NADH or NADPH oxidase activity was
measured by chemiluminescence in a scintillation vial containing HEPES
buffer, 250 µmol/L lucigenin, in 2 mL buffer phosphate. The
chemiluminescence, which occurred over the ensuing 5 minutes in
response to the addition of either 100 µmol/L NADH or 100
µmol/L NADPH, was recorded. No activity could be measured in the
absence of NADH or NADPH. Reactions were initiated by the addition of
20 µL homogenate. To determine the
·O2- dependency of the
lucigenin-enhanced chemiluminescence obtained from vascular
homogenates, we examined the effect of
Cu2+/Zn2+ superoxide
dismutase (SOD) (2000 U/mL) on
·O2- production after
stimulation of homogenates with NADH. In some experiments,
membranes and cytosol were separated by centrifugation
(50 000g for 30 minutes). Twenty-five microliters of either
the supernatant or the particulate fraction were used to examine NADH
oxidasedependent and NADPH oxidasedependent
·O2- production of
these subcellular fractions.
Endothelium-Dependent and
Endothelium-Independent Relaxations
After washing, each aorta was cut into 2- to 3-mm rings (6 per
rat). The rings were suspended in a vessel that contained 10 mL of
Krebs-Henseleit solution with the following composition (in mmol/L):
118.4 NaCl, 4.74 KCl, 1.18 MgSO2, 0.7
H2O, 1.19
KH2PO4, 2.52
CaCl2, 0.2 H2O, 25
NaHCO3, and 11.5 glucose (pH, 7.34). The solution
was oxygenated with a 95% O25%
CO2 mixture and maintained at 37°C in a
thermostated bath. Two stainless steel wires were inserted into the
vascular lumen; one was anchored to a stationary support and the other
was connected to a force isometric transducer. The rings were incubated
for 60 minutes for equilibration at a resting tension of 2g
with buffer exchanges every 15 minutes during this period. Changes in
isometric forces were analyzed and recorded by an Isolated
Organs Data Acquisition Program (Proto5). The rings were then maximally
contracted with norepinephrine (10-7
mol/L), and once a plateau had been reached, the
endothelium-dependent and
endothelium-independent relaxations were studied by
plotting the concentration-response curves for the responses to
10-9 to 10-5 mol/L
acetylcholine (Ach) and to 10-9 to
10-6 mol/L sodium nitroprusside (SNP),
respectively. Endothelium-dependent and
endothelium-independent relaxations were expressed as
percentages of decline of the contraction induced by
norepinephrine. These values were then plotted against the
negative logarithm of the agonist dose to produce dose-response curves.
Dose-response curves were analyzed, and the
EC50 value (the concentration for half-maximal
response) for relaxation of each ring was calculated by logistic
analysis and expressed as the pD2 defined
as -log (EC50).
Reverse TranscriptionPolymerase Chain Reaction for
p22phox
Total RNA was extracted from homogenized thoracic
aortas with the use of Ultraspec RNA reagent. mRNA was isolated from
total RNA with the Oligotex mRNA kit (Qiagen), and mRNA concentration
was determined spectrometrically. The expression of p22phox
was quantified in the aorta by a competitive reverse
transcriptionpolymerase chain reaction (RT-PCR) method, as described
by Gilliland et al.19 On the basis of rat
p22phox cDNA sequence,20 the
oligonucleotides 5'-GCTCATCTGTCTGCTGGAGTA-3' and
5'-ACGACCTCATCTGTCACTGGA-3' were selected as sense and antisense
primers, respectively. The p22phox-specific primers
amplified a 435-bp PCR product. The identity of this PCR
product was verified by sequencing. The heterologous DNA template
(p22phox competitor) was constructed with the use of a
PCR-MIMIC construction kit (Clontech), following the manufacturers
instructions. The obtained 318-bp p22phox competitor
contained the p22phox genespecific sequences incorporated
at the ends. This 318-bp fragment was cloned in a pGEMT vector
(Promega), linearized by digestion with Sca I, and subjected
to in vitro transcription into RNA. The purified
p22phox-construct RNA was quantified
spectrometrically.
Both RT and PCR were performed in a single tube with gene-specific primers and specific target RNAs, with the use of the Superscript 1-step RT-PCR System (Life Technologies). RT-PCR was performed with constant amounts of aortic mRNA (35 ng) together with a range of amounts between 106 and 105 molecules of competitor RNA. RT-PCR reaction mixture (50 µL) contained aortic and competitor RNA, a buffer containing 0.2 mmol/L of each dNTP, and 1.2 mmol/L MgSO4, 20 pmol/L of primer, 20 U of Rnase inhibitor (Pharmacia Biotech Inc), and 1 µL of a RT/Taq Mix containing a mixture of Superscript II Reverse Transcriptase and Taq DNA Polymerase. All components necessary for RT-PCR were mixed in 1 tube, and RT (55°C for 30 minutes and then to 94°C for 2 minutes) was automatically followed by PCR cycling (35 cycles with a temperature profile of 94°C for 20 seconds, 60°C for 25 seconds, and 72°C for 1 minute and finally 5 minutes at 72°C for quantification of p22phox mRNA) without additional steps. The PCR products were run on a 2% agarose gel, stained with ethidium bromide, visualized by UV illumination, and photographed. The amounts of target and competitor PCR product were quantified by densitometric scanning of the film negative. To correct for differences in size of target (435 bp) and competitor (318 bp) p22phox PCR products, the amounts of competitor PCR product were multiplied by 1.368 (435/318). The ratio of target to competitor PCR product was plotted against the number of competitor construct molecules on a log-log scale. At the point in which equal molar amounts of target and competitor product were yielded by PCR (ie, competition ratio=1), the original number of transcript in the aortic sample was defined by the known input of competitor construct molecules.
Vascular Morphology
Before the animals were killed, they were weighted and
anesthetized (sodium thiopental, 30 mg/kg IP). Subsequently,
the thoracic aorta was fixed by retrograde perfusion as we have
previously described.21 In brief, the aorta was cannulated
with a polyethylene catheter, the heart was arrested in
diastole by an intracarotid injection of KCl (1.0 mol/L, 1
mL), and the right atria were incised to allow drainage of blood and
perfusate. After initial perfusion with normal saline buffer to
wash the blood, 4% paraformaldehyde was perfused for 5
minutes at a pressure equal to the mean arterial pressure
determined before the animals were killed. The thoracic aorta was
excised and transversally cut in 8 slices. The slices were
alternatively separated into 2 groups, postfixed for 5 hours by
immersion in buffered 4% paraformaldehyde and 10%
formalin, respectively, and finally, dehydrated and embedded in
paraffin. Transversal sections (4 µm in thickness) of the
thoracic aorta were obtained from the 4
paraformaldehyde-fixed, paraffin-embedded specimens.
Media thickness (MT) and cross-sectional area (CSA) were determined by
morphometry with an automated image analysis system (Visilog
4.1.5, Noesis) as previously described by van Gorp et
al.22 For this purpose, 1 section of each specimen (4 from
each rat) was stained for elastin fibers. Sections were
analyzed under the microscope (x4), and images of the whole
aortic ring were digitized (final resolution of 85.5
mm2/pixel). Stained elastic lamellae were
segmented by interactive gray-level thresholding, and after binary
processing and analysis, CSA and MT were obtained. CSA reflects
the degree of arterial hypertrophy better than
MT because it is not influenced by the variations in the perfusion
pressure.23
A monoclonal mouse antibody against rat monocyte/macrophages (ED1, Serotec)24 at a concentration of 1:100 in PBS was applied for 20 minutes. In control experiments, we checked that ED1 is specific for rat monocyte macrophages and does not recognize granulocytes, lymphocytes, endothelial cells, or smooth muscle cells. Fluorescein-conjugated goat anti-mouse antibody (Dakopatts) was used as a second antibody at a concentration of 1:40.
Statistical Analysis
Data are expressed as mean±SEM. Differences among the 5 groups
of rats were tested by a 1-way ANOVA. A Scheffés post hoc test
was used to examine differences between groups when significance was
indicated. Probability values <0.05 were considered significant.
| Results |
|---|
|
|
|---|
|
p22phox mRNA Expression
In preliminary experiments, we proved that there were no
differences in the rate of transcription of the target and competitor
sequences. A representative competitive RT-PCR
experiment of aortic p22phox mRNA in young and adult rats is
shown in Figure 1a. In initial
experiments, p22phox was amplified from cDNA in the presence
of several serial dilutions of the p22phox competitor. The
results of these experiments enabled us to find the most appropriate
amounts of the p22phox competitor. Thus, definitive
experiments were performed with different amounts of p22phox
competitor comprised between 105 and
106 molecules. No differences in the
p22phox mRNA level were found between
WKY16 and SHR16 (3685±813
versus 4218±707 molecules of p22phox mRNA/ng mRNA) (Figure 1b). In contrast, p22phox mRNA level was 2.5-fold
higher in SHR30 than in
WKY30 (10 455±1056 versus 4221±349 molecules
of p22phox mRNA/ng mRNA, P<0.01) (Figure 1b). Furthermore, the p22phox mRNA level was greater
(P<0.01) in SHR30 than in
SHR16. After treatment with irbesartan,
p22phox mRNA expression was lower (P<0.01) in
SHR30-I (3456 molecules of p22phox
mRNA/ng mRNA) than in SHR30, and the values in
treated SHR were similar to those measured in
WKY30 (Figure 1b).
|
NADH/NADPH Oxidase Activity
No differences were found between WKY16 and
SHR16 in NADH oxidase activity (5.45±0.66 versus
5.96±0.77 nmol
·O2- ·min-1 ·mg-1) and NADPH oxidase activity
(1.92±0.16 versus 1.73±0.27 nmol
·O2- ·min-1 ·mg-1) (Figure 2). In contrast, both activities were
higher (P<0.01) in SHR30 than in
WKY30 (11.01±0.81 versus 5.81±0.74 nmol
·O2- ·min-1 ·mg-1 for NADH oxidase activity; 5.09±0.41
versus 2.21±0.19 nmol
·O2- ·min-1 ·mg-1 for NADPH oxidase activity). The
activity of the oxidase was lower (P<0.01) in
SHR30-I than in SHR30
(5.50±0.53 nmol
·O2- ·min-1 ·mg-1 for NADH oxidase activity and
2.31±0.27 nmol
·O2- ·min-1 ·mg-1 for NADPH oxidase activity) (Figure 2).
|
To assess the cellular source of increased NADH/NADPH oxidase activity in the vascular wall, some experiments were performed in deendothelized preparations. Although removal of the endothelium diminished slightly the NADH oxidase activity in aortic homogenates from SHR30 (with endothelium, 10.57±0.17 nmol ·O2- ·min-1 ·mg-1; without endothelium, 8.62±0.51 nmol ·O2- ·min-1 ·mg-1), the difference was not statistically significant.
To determine the ·O2- dependency of the lucigenin-enhanced chemiluminescence obtained from homogenates of rat aorta, we examined the effect of native Cu2+/Zn2+ SOD. As shown in Figure 3, SOD at very high concentrations (2000 U/mL) was effective in reducing the chemiluminescence signal in response to stimulation with NADH.
|
NADH-dependent and NADPH-dependent oxidase activities in adult rats were located predominantly in the particulate fraction (Figure 4). NADH-driven ·O2- production measured in the particulate fraction was higher (P<0.01) in SHR30 than in WKY30 (159±16 versus 59±6 nmol · min-1 ·mg-1). NADPH-driven ·O2- production measured in the particulate fraction was also higher (P<0.01) in SHR30 than in WKY30 (48±3.7 versus 11.9±2.1 nmol · min-1 ·mg-1). Cytosolic activity was minimal in all the animals tested (Figure 4).
|
High concentrations of lucigenin can produce a redox cycle with flavin-containing enzymes, leading to artifactual increases in estimates of ·O2-.25 This does not occur with low concentrations of lucigenin (5 µmol/L).26 Experiments with 5 µmol/L lucigenin revealed that NADH oxidase activity was greater (P<0.01) in aortas from SHR30 than in aortas from WKY30 (99±3 vs 56±3 counts · min-1 ·µg-1).
Vascular Relaxations
Whereas no differences in the maximal relaxations in response to
Ach were observed between WKY16 and
SHR16, this parameter was lower
(P<0.05) in SHR30 than in
WKY30 (Table). Furthermore, the response
to Ach was lower (P<0.05) in SHR30
than in SHR16 (Table). Irbesartan-treated
SHR exhibited a normal response to Ach (Table). There were no
significant differences in the sensitivity to Ach
(pD2 values) among the different groups of
animals (Table).
Maximum endothelium-independent relaxations to SNP were reached at the same concentration (3x10-6 mol/L) in hypertensive and normotensive rats, irrespective of age and treatment. There were no significant differences in the pD2 values between WKY16 and SHR16 (Table). Nevertheless, pD2 values were lower (P<0.05) in SHR30 and SHR30-I than in WKY30 (Table).
Morphological Analysis
There were no differences in MT and CSA between
WKY16 and SHR16
(Table). Otherwise, MT and CSA were greater (P<0.05)
in SHR30 than in WKY30 and
SHR16 (Table). Although the values of MT
and CSA were lower in SHR30-I than in
SHR30, the difference was not significant
(Table). No differences were observed in these 2
parameters between SHR30-I and
WKY30 (Table).
In WKY and SHR, immunofluorescence did not reveal any ED1-positive cells in the aorta. The absence of monocyte-macrophages in SHR aorta was confirmed by light microscopy and morphological evaluation.
| Discussion |
|---|
|
|
|---|
The NADH/NADPH oxidase is expressed in endothelial cells,12 VSMCs,12 16 27 adventitial fibroblasts,14 28 and inflammatory neutrophils.29 Although we did not perform in situ hybridization to determine which cell type(s) overexpress p22phox mRNA, several findings support a role for VSMCs as the potential source for oxidase overactivity found in adult SHR. First, the examination of NADH/NADPH activity was performed in aortas in which the adventitial tissue had been previously removed. Second, deendothelialization did not affect the level of NADH/NADPH oxidase activity. Third, increased NADH/NADPH oxidase activity was associated with hypertrophy of the media. Fourth, although it has been reported that in the aortas of SHR exist an augmented infiltration of monocyte-macrophage cells compared with the aortas of WKY,30 we did not observe such an abnormality in the aortas of adult SHR after microscopic examination. Further, the preferred substrate for oxidases in macrophages and neutrophils is NADPH rather than NADH.27
It is unclear which factors may be involved in upregulation of p22phox mRNA expression present in the aortas of adult SHR. It has been reported that hydralazine decreases both blood pressure and NADPH oxidase activity in the aortas of rats with experimentally induced hypertension.31 Thus, it is possible that the increase in blood pressure is the stimulus that induces p22phox mRNA expression in the aortas of adult SHR. However, it has been shown that norepinephrine-induced hypertension does not increase vascular NADH/NADPH oxidase activity.17 The same authors have reported that infusion of low amounts of angiotensin II that do not increase blood pressure results in the increase in this oxidase activity. Moreover, we found that p22phox mRNA expression was normal in young SHR exhibiting the same degree of elevation in blood pressure than did adult SHR. It therefore appears that long-term exposure to arterial hypertension is necessary to induce p22phox overexpression in SHR aorta. Alternatively, other nonhemodynamic factors may be also involved in this alteration (ie, tissue hormones and cytokines).
One of these candidate factors is angiotensin II. As previously mentioned, it has been found that p22phox mRNA expression was elevated in rats receiving angiotensin II infusion.31 This effect was inhibited by treatment with losartan, suggesting that it was mediated by the interaction of angiotensin II with AT1 receptors at the vascular wall. In addition, angiotensin II has been found to stimulate p22phox expression and ·O2- production in VSMCs.16 Exaggerated production of angiotensin II32 and enhanced expression of both AT1 receptor and angiotensin-converting enzyme33 have been reported in vessels of SHR compared with WKY. Furthermore, an age-dependent increase of vascular angiotensin-converting enzyme activity in SHR has been shown.34 Altogether these data would suggest that high levels of vascular angiotensin II can participate in p22phox overexpression in the aortas of adult SHR. This possibility is further supported by our findings that both p22phox mRNA expression and NADH/NADPH oxidase activity are normalized in irbesartan-treated SHR despite a noncomplete normalization of blood pressure.
It has been suggested that the development of endothelial dysfunction is linked to an exaggerated production of ·O2- in aortas from SHR.8 An enhanced production of ·O2- may result in inactivation of NO and generation of peroxynitrite.35 The resulting decrease in NO availability might be involved in the impairment of NO-dependent relaxations.2 3 8 9 10 Thus, oxidative degradation of NO caused by increased ·O2- secondary to overactivity of NADH/NADPH oxidase likely explains the diminished response to Ach observed in the aortas of adult SHR. This is further supported by the finding that responses to Ach are normal in irbesartan-treated SHR, which exhibit normal NADH/NADPH oxidase activity. Of course, our results do not exclude a role for other potential sources of ·O2- (endothelial NO synthase, xanthine oxidase) in the vascular wall of adult SHR. On the other hand, the observation that responses to SNP are altered in both untreated and treated SHR suggests that other molecular alterations (ie, diminished expression and activity of VSMC guanylate cyclase)36 37 may also contribute to impaired vasodilatory responsiveness in SHR.
On the other hand, it is possible that ·O2- is also involved in vascular hypertrophy. Recently, it has been shown that ·O2- stimulates the proliferation of VSMCs.11 In addition, a role for NADH/NADPH oxidasederived ·O2- and H2O2 has been proposed in angiotensin IIinduced VSMC growth.12 Therefore, the association of NADH/NADPH oxidase overactivity with medial hypertrophy in the aortas of adult SHR suggests a contributing role for the enzyme in vascular wall remodeling. The finding that the dimensions of the aortic wall were not completely normalized in irbesartan-treated SHR suggests that the maintenance of increased levels of blood pressure after treatment may also account for the persistence of a certain degree of aortic hypertrophy in these rats.
In summary, we reported that NADH/NADPH oxidase activity is abnormally increased in the aortic wall of adult SHR and that this abnormality is associated with upregulated p22phox mRNA expression. Our findings suggest that long-term exposure to hypertension, possibly combined with other factors (ie, local overproduction of angiotensin II), may play a role in p22phox upregulation and enzyme overactivity in the media layer from the aortas of these rats. Enhanced NADH/NADPH oxidasemediated ·O2- production might contribute to functional and structural alterations present in the aortas of adult SHR. Further experiments are necessary to elucidate the precise mechanism through which chronic blockade of AT1 receptors prevents overstimulation of vascular NADH/NADPH oxidase in this genetic model of hypertension. The significance of these experimental results is underlined by clinical data indicating the occurrence of increased ·O2- production in humans with essential hypertension.38 39
| Acknowledgments |
|---|
Received October 11, 1999; first decision November 24, 1999; accepted December 16, 1999.
| References |
|---|
|
|
|---|
-subunit cloning and expression
in rat aortic smooth muscle cells. Biochim Biophys Acta. 1995;1231:215219.[Medline]
[Order article via Infotrieve]
.
Biochem J. 1989;263:539545.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
X. Zhou, H. G. Bohlen, S. J. Miller, and J. L. Unthank NAD(P)H oxidase-derived peroxide mediates elevated basal and impaired flow-induced NO production in SHR mesenteric arteries in vivo Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1008 - H1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yogi, C. Mercure, J. Touyz, G. E. Callera, A. C.I. Montezano, A. B. Aranha, R. C. Tostes, T. Reudelhuber, and R. M. Touyz Renal Redox-Sensitive Signaling, but Not Blood Pressure, Is Attenuated by Nox1 Knockout in Angiotensin II-Dependent Chronic Hypertension Hypertension, February 1, 2008; 51(2): 500 - 506. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Paravicini and R. M. Touyz NADPH Oxidases, Reactive Oxygen Species, and Hypertension: Clinical implications and therapeutic possibilities Diabetes Care, February 1, 2008; 31(Supplement_2): S170 - S180. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Macarthur, T. C. Westfall, and G. H. Wilken Oxidative stress attenuates NO-induced modulation of sympathetic neurotransmission in the mesenteric arterial bed of spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H183 - H189. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Korshunov, M. Daul, M. P. Massett, and B. C. Berk Axl Mediates Vascular Remodeling Induced by Deoxycorticosterone Acetate Salt Hypertension Hypertension, December 1, 2007; 50(6): 1057 - 1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. E. Rush, J. Quadrilatero, A. S. Levy, and R. J. Ford Chronic Resveratrol Enhances Endothelium-Dependent Relaxation but Does Not Alter eNOS Levels in Aorta of Spontaneously Hypertensive Rats Experimental Biology and Medicine, June 1, 2007; 232(6): 814 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Miller, L. E. Norton, M. P. Murphy, M. C. Dalsing, and J. L. Unthank The role of the renin-angiotensin system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth impairment Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2523 - H2531. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Angermayr, M. Fernandez, M. Mejias, J. Gracia-Sancho, J. C. Garcia-Pagan, and J. Bosch NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats Gut, April 1, 2007; 56(4): 560 - 564. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Szasz, K. Thakali, G. D. Fink, and S. W. Watts A Comparison of Arteries and Veins in Oxidative Stress: Producers, Destroyers, Function, and Disease Experimental Biology and Medicine, January 1, 2007; 232(1): 27 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahman, A. Nishiyama, P. Guo, Y. Nagai, G.-X. Zhang, Y. Fujisawa, Y.-Y. Fan, S. Kimura, N. Hosomi, K. Omori, et al. Effects of Adrenomedullin on Cardiac Oxidative Stress and Collagen Accumulation in Aldosterone-Dependent Malignant Hypertensive Rats J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1323 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Paravicini and R. M. Touyz Redox signaling in hypertension Cardiovasc Res, July 15, 2006; 71(2): 247 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nagata, M. Takahashi, K. Sawai, T. Tagami, T. Usui, A. Shimatsu, Y. Hirata, and M. Naruse Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase Activity Hypertension, July 1, 2006; 48(1): 165 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, K. Witte, M. August, I. Brausch, U. Godtel-Armbrust, A. Habermeier, E. I. Closs, M. Oelze, T. Munzel, and U. Forstermann Reversal of Endothelial Nitric Oxide Synthase Uncoupling and Up-Regulation of Endothelial Nitric Oxide Synthase Expression Lowers Blood Pressure in Hypertensive Rats J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2536 - 2544. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Dai, X. Cao, and D. L. Kreulen Superoxide anion is elevated in sympathetic neurons in DOCA-salt hypertension via activation of NADPH oxidase Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1019 - H1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Jalil, A. Perez, M. P. Ocaranza, J. Bargetto, A. Galaz, and S. Lavandero Increased Aortic NADPH Oxidase Activity in Rats With Genetically High Angiotensin-Converting Enzyme Levels Hypertension, December 1, 2005; 46(6): 1362 - 1367. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Racasan, B. Braam, H. A. Koomans, and J. A. Joles Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon Am J Physiol Renal Physiol, April 1, 2005; 288(4): F626 - F636. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kimura, G.-X. Zhang, A. Nishiyama, T. Shokoji, L. Yao, Y.-Y. Fan, M. Rahman, and Y. Abe Mitochondria-Derived Reactive Oxygen Species and Vascular MAP Kinases: Comparison of Angiotensin II and Diazoxide Hypertension, March 1, 2005; 45(3): 438 - 444. [Abstract] [Full Text] [PDF] |
||||
|
|